Literature DB >> 18154419

Cyclosporine in the treatment of membranoproliferative glomerulonephritis.

Nazila Bagheri1, Eghlim Nemati, Khosro Rahbar, Ali Nobakht, Behzad Einollahi, Saeed Taheri.   

Abstract

BACKGROUND: Therapeutic approach to patients with idiopathic membranoproliferative glomerulonephritis is still controversial. Because it is more common in developing countries, the studies about it are limited.
METHODS: We used cyclosporine to treat 18 patients with membranoproliferative glomerulonephritis who were resistant to other treatment protocols such as using aspirin, dipyridamole, or steroids. All patients were treated with cyclosporine plus low-dose prednisone and were followed for an average 108 weeks.
RESULTS: Partial or complete remission of proteinuria occurred in 94% of the patients (P<0.01). Relapse occurred in one (14.2%) of remitters after discontinuation of the drug. But the remainder stayed in remission to the end of the observation period. There was a 507% decrease in the baseline creatinine clearance in one patient (5.5%).
CONCLUSION: These results suggest that cyclosporine may be an effective therapeutic agent in the treatment of resistant idiopathic membranoproliferative glomerulonephritis. Although the response is appeared later than other types of glomerulonephritis, but a long-term decrease in proteinuria and preservation of filtration function were observed in a significant proportion of the treated patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18154419     DOI: 08111/AIM.008

Source DB:  PubMed          Journal:  Arch Iran Med        ISSN: 1029-2977            Impact factor:   1.354


  6 in total

Review 1.  C3 Glomerulopathy.

Authors:  Magdalena Riedl; Paul Thorner; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2016-04-07       Impact factor: 3.714

Review 2.  Rituximab for Treatment of Membranoproliferative Glomerulonephritis and C3 Glomerulopathies.

Authors:  Michael Rudnicki
Journal:  Biomed Res Int       Date:  2017-05-09       Impact factor: 3.411

Review 3.  Clinical and Pathophysiological Insights Into Immunological Mediated Glomerular Diseases in Childhood.

Authors:  Antonio Mastrangelo; Jessica Serafinelli; Marisa Giani; Giovanni Montini
Journal:  Front Pediatr       Date:  2020-05-12       Impact factor: 3.418

4.  Membranoproliferative glomerulonephritis and C3 glomerulopathy in children: change in treatment modality? A report of a case series.

Authors:  Giuseppina Spartà; Ariana Gaspert; Thomas J Neuhaus; Marcus Weitz; Nilufar Mohebbi; Urs Odermatt; Peter F Zipfel; Carsten Bergmann; Guido F Laube
Journal:  Clin Kidney J       Date:  2018-02-28

Review 5.  Membranoproliferative glomerulonephritis.

Authors:  Bassam Alchi; David Jayne
Journal:  Pediatr Nephrol       Date:  2009-11-12       Impact factor: 3.714

6.  Therapy and outcomes of C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis.

Authors:  Priyanka Khandelwal; Swati Bhardwaj; Geetika Singh; Aditi Sinha; Pankaj Hari; Arvind Bagga
Journal:  Pediatr Nephrol       Date:  2020-09-04       Impact factor: 3.714

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.